Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Join our "Open REC Sports" for inclusive and laid-back sport activities welcoming individuals of all skill levels and backgrounds. These sport activities, included with your Recreation membership, ...
I Tested Starlink’s Low-Cost $80-Per-Month Plan: It's Not the Downgrade I Expected By Brian Westover A Free One-Click Fix for Slow Computers? I Put Microsoft's PC Manager App to the Test By Michael ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results